Cite
MLA Citation
Thierry Facon et al.. “Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.” Lancet oncology, vol. 22, no. 11, 2021, pp. 1582–1596. http://access.bl.uk/ark:/81055/vdc_100145644746.0x00000e